Pasithea Therapeutics (KTTA) Insider Trading & Ownership $3.80 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Pasithea Therapeutics (NASDAQ:KTTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.30%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$347,953.20Number OfInsiders Selling(Last 3 Years)0 Get KTTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Pasithea Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KTTA Insider Buying and Selling by Quarter Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Pasithea Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/2/2023Lawrence SteinmanDirectorBuy1,500$8.60$12,900.00 10/17/2022David DelaneyMajor ShareholderBuy50$22.20$1,110.00 9/28/2022Eric ShahinianMajor ShareholderBuy2,882$23.80$68,591.60 8/29/2022Eric ShahinianMajor ShareholderBuy250$23.40$5,850.00 8/19/2022Avi GellerMajor ShareholderBuy2,732$26.00$71,032.00 8/17/2022Eric ShahinianMajor ShareholderBuy7,788$24.20$188,469.60 (Data available from 1/1/2013 forward) KTTA Insider Trading Activity - Frequently Asked Questions Who is on Pasithea Therapeutics's Insider Roster? The list of insiders at Pasithea Therapeutics includes Avi Geller, David Delaney, Eric Shahinian, and Lawrence Steinman. Learn more on insiders at KTTA. What percentage of Pasithea Therapeutics stock is owned by insiders? 16.30% of Pasithea Therapeutics stock is owned by insiders. Learn more on KTTA's insider holdings. Which Pasithea Therapeutics insiders have been buying company stock? The following insider purchased KTTA shares in the last 24 months: Lawrence Steinman ($12,900.00). How much insider buying is happening at Pasithea Therapeutics? Insiders have purchased a total of 1,500 KTTA shares in the last 24 months for a total of $12,900.00 bought. More Insider Trading Tools from MarketBeat Related Companies Chemomab Therapeutics Insider Selling Minerva Neurosciences Insider Selling Synlogic Insider Selling Biora Therapeutics Insider Selling Indaptus Therapeutics Insider Selling Unicycive Therapeutics Insider Selling Talphera Insider Selling Sensei Biotherapeutics Insider Selling KALA BIO Insider Selling MIRA Pharmaceuticals Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:KTTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
